Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomes.
Vaz J, Piver R, Brzezinska B, Suhner J, Sareddy S, Vuppala P, Vernon M, Xu H, Rungruang B, Johnson M, Higgins RV, Ghamande S, Richardson KP, McIndoe R, Purohit S, Mysona D. Vaz J, et al. Among authors: ghamande s. Gynecol Oncol. 2024 Oct;189:129-136. doi: 10.1016/j.ygyno.2024.07.685. Epub 2024 Aug 7. Gynecol Oncol. 2024. PMID: 39116830
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Ghamande SA, Silverman MH, Huh W, Behbakht K, Ball G, Cuasay L, Würtz SO, Brunner N, Gold MA. Ghamande SA, et al. Gynecol Oncol. 2008 Oct;111(1):89-94. doi: 10.1016/j.ygyno.2008.06.028. Epub 2008 Aug 28. Gynecol Oncol. 2008. PMID: 18760451 Clinical Trial.
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ. Arend RC, et al. Among authors: ghamande s. Gynecol Oncol. 2020 Feb;156(2):301-307. doi: 10.1016/j.ygyno.2019.12.002. Epub 2019 Dec 20. Gynecol Oncol. 2020. PMID: 31870556 Clinical Trial.
A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
Tran LKH, Tran PMH, Mysona DP, Purohit SB, Myers E, Lee WS, Dun B, Xu D, Liu H, Hopkins D, Nechtman J, Scelsi CL, Mittal PK, Kleven D, Wallbillich JJ, Rungruang B, Ghamande S, She JX. Tran LKH, et al. Among authors: ghamande s. Gynecol Oncol. 2020 May;157(2):340-347. doi: 10.1016/j.ygyno.2020.02.015. Epub 2020 Feb 14. Gynecol Oncol. 2020. PMID: 32067813
187 results